

# Cutting through the noise: How do GEP-NET patients stand to benefit from PRRT?

Monday 20 September 2021  
**08:45–10:15 CEST**

Channel 6

Virtual satellite symposium



## Marianne Pavel

Senior Physician and Chair of Endocrinology, Friedrich-Alexander University of Erlangen, Erlangen, Germany



## Enrique Grande

Director, Medical Oncology Program and Clinical Research Lead, MD Anderson Cancer Center, Madrid, Spain



## Nicola Fazio

Director, Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, Director, Programme in Digestive and Neuroendocrine Tumours, European Institute of Oncology, Milan, Italy

## Invitation from the Chair

Dear colleague,

It is my pleasure to invite you to this virtual satellite symposium, sponsored by Advanced Accelerator Applications, a Novartis company, to be held during the ESMO Congress 2021. The expert faculty will draw on new data from the pivotal NETTER-1 trial with [<sup>177</sup>Lu]Lu-DOTA-TATE to explore how patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) stand to benefit from peptide receptor radionuclide therapy (PRRT). We will discuss the final overall survival data from the trial, including the potential impact of patient and tumour characteristics, and the effect of treatment on burdensome symptoms and quality of life. Alongside, we will consider how the data advance our understanding of meaningful study endpoints and their relevance for clinical decision making.

Please join us to explore what this means for your patients and the future use of PRRT in GEP-NETs.

Yours sincerely,

Professor Marianne Pavel  
 University of Erlangen  
 Erlangen, Germany  
 Symposium Chair



## AGENDA

| Time (CEST) | Session   | Speaker                            |
|-------------|---|------------------------------------|
| 08:45–08:50 | Welcome and introduction  | Marianne Pavel                     |
| 08:50–09:05 | [ <sup>177</sup> Lu]Lu-DOTA-TATE, overall survival data from NETTER-1 trial and sub-analyses: Who benefits and by how much? | Enrique Grande                     |
| 09:05–09:15 | What is a meaningful endpoint for patients with GEP-NETs?   | Marianne Pavel                     |
| 09:15–09:30 | Tolerability and quality of life: Where do we stand now?  | Nicola Fazio                       |
| 09:30–09:45 | Putting the data into context: What does this all mean for my patients and the future use of PRRT?                          | All faculty                        |
| 09:45–10:15 | Q&A and conclusion  | All faculty, led by Marianne Pavel |

This symposium is only accessible to healthcare professionals registered to ESMO 2021